DongKoo Bio & Pharma Co., Ltd. Logo

DongKoo Bio & Pharma Co., Ltd.

A biopharmaceutical company specializing in dermatology and stem cell therapies.

006620 | KO

Overview

Corporate Details

ISIN(s):
KR7006620009
LEI:
Country:
South Korea
Address:
서울특별시 송파구 법원로 114, B동 14층, 송파구

Description

DongKoo Bio & Pharma Co., Ltd. is a biopharmaceutical company that manufactures and sells a range of pharmaceuticals and health supplements. The company holds a leading position in the dermatology prescription market, with a product portfolio that includes antihistamines, analgesics, antipyretics, and digestants. Strategically expanding beyond traditional pharmaceuticals, DongKoo Bio & Pharma is focused on the biotechnology sector, particularly the development of stem cell-based therapies. This growth is pursued through an "Open Innovation" model to build a pipeline of differentiated products, supported by its research centers and PIC/s compliant GMP manufacturing facilities.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2024-05-23 00:00
[기재정정]주식매수선택권부여에관한신고
Korean 26.6 KB
2024-05-16 00:00
분기보고서 (2024.03)
Korean 1.5 MB
2024-05-03 00:00
주식등의대량보유상황보고서(일반)
Korean 110.8 KB
2024-05-02 00:00
신탁계약해지결과보고서
Korean 28.2 KB
2024-04-04 00:00
주식등의대량보유상황보고서(일반)
Korean 114.1 KB
2024-03-28 00:00
정기주주총회결과
Korean 23.6 KB
2024-03-20 00:00
감사보고서제출
Korean 25.0 KB
2024-03-20 00:00
사업보고서 (2023.12)
Korean 2.0 MB
2024-03-13 00:00
주주총회소집결의
Korean 11.2 KB
2024-03-13 00:00
[기재정정]현금ㆍ현물배당결정
Korean 15.8 KB
2024-03-13 00:00
주주총회소집공고
Korean 1.2 MB
2024-03-13 00:00
매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 10.9 KB
2024-02-02 00:00
신탁계약에의한취득상황보고서
Korean 22.2 KB
2023-12-22 00:00
주식등의대량보유상황보고서(일반)
Korean 112.8 KB
2023-12-14 00:00
주주명부폐쇄기간또는기준일설정
Korean 4.1 KB

Automate Your Workflow. Get a real-time feed of all DongKoo Bio & Pharma Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for DongKoo Bio & Pharma Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for DongKoo Bio & Pharma Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.